Neurogenx

What Neurogenx does

Neurogenx Inc. is a privately held medical technology company headquartered in Lansing, Michigan, that develops and commercializes the FDA 510-K cleared NervePro 2.0 device for the treatment of peripheral neuropathy and related chronic nerve conditions. The device delivers a proprietary high-frequency electronic wave (60,000Hz down to 400Hz) through transcutaneous adhesive electrode patches using a bio-compatible waveform that mimics the body's own action potentials, with an optional Combination Electrochemical Therapy (CET) protocol that pairs the electronic signal with low-dose Marcaine nerve blocks during early sessions. The company reports an 87% patient success rate in resolving or reducing neuropathy symptoms, with independent studies documenting an average 165.4% increase in nerve fiber density. Neurogenx also markets the Nerve Health Solution nutritional supplement (L-Arginine and L-Citrulline, formulated around Dr. Louis Ignarro's Nitric Oxide research) exclusively through healthcare professionals.

The company operates a two-tier provider distribution model: a Preferred Provider program for individual practices and a standalone NerveCenter model that grants geographic exclusivity. Providers purchase the NervePro 2.0 at approximately $50,000 (with a $5,000 year-end discount and Section 179 tax benefits available) and access the Solutions Program, which bundles clinical training, customized websites, digital and print marketing collateral, physician referral toolkits, financing software, and call-center support. Patient treatment is delivered in 20-40 minute sessions, typically 1-2 visits per week over 8-16 weeks (16-24 sessions total), with cash and insurance billing handled at the practice level. Neurogenx derives revenue from device hardware sales, wholesale supplement distribution, and ancillary program fees.

Founded in 2012, Neurogenx serves neurologists, primary care physicians, podiatrists, and chiropractors across hundreds of U.S. locations. The company employs 1-10 people, has not disclosed external funding or institutional investors, and has no public listing. Its strategic positioning emphasizes non-narcotic, non-invasive neuropathy care and targets providers seeking differentiated, cash-friendly service lines in a U.S. patient population estimated at 20-30 million peripheral neuropathy sufferers.

Name

Neurogenx

Legal name

Neurogenx Inc.

Website

https://neurogenx.com

Company type

Private

Founded year

2012

Operating status

Operating

Headcount range

1–10 employees

Short description

Neurogenx is a privately held Michigan-based medical technology company that sells the FDA-cleared NervePro 2.0 high-frequency electromedical device and associated treatment protocols to U.S. healthcare providers (neurologists, primary care, podiatrists, chiropractors) for the in-office treatment of peripheral neuropathy and chronic nerve conditions, supplemented by a professional-channel nutritional supplement line.

Ownership category

akta.pro rank

Product category

Neuropathy Treatment Medical Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS) (HLAHAEAK)

Keywords

• Neuropathy treatment devices
• Electromedical therapy equipment
• Peripheral neuropathy care
• Nerve health supplements
• FDA-cleared medical devices

Headquarters

HQ city

Lansing

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Marketing or Sales, Operations, Supply Chain

Revenue model

1. NervePro 2.0 Device Sales: Neurogenx sells the NervePro 2.0 FDA-cleared medical device to healthcare providers (Preferred Providers and NerveCenter operators). Providers purchase the device as a capital equipment item to deliver in-office neuropathy treatment. A $5,000 year-end discount is offered, and Section 179 tax benefits are available for equipment purchases.
2. Neuropathy Treatment Protocol Fees: Providers administer Neurogenx treatments to patients on a fee-per-visit or bundled protocol basis. Treatment typically involves 16-24 sessions over 8-16 weeks, with each session lasting 20-40 minutes. Insurance coverage varies by locale; the company also supports cash-based models. The company provides financing options and deferred payment plans for patients.
3. Nerve Health Solution Supplements: Neurogenx sells nutritional supplements (Nerve Health Solution) featuring L-Arginine and L-Citrulline for nerve health support. Products are available only through healthcare professionals at wholesale pricing for medical and wellness professionals, and retail pricing for patients.

Pricing tiers

Go-to-market motion1 record

Distribution channels5 records

Marketing channels9 records

Core offering

Neurogenx develops, manufactures, and distributes the FDA 510-K cleared NervePro 2.0 electromedical device, which delivers high-frequency electronic wave therapy (60,000Hz to 400Hz) via transcutaneous adhesive electrode patches to treat peripheral neuropathy and chronic nerve conditions. The company also offers the proprietary Combination Electrochemical Therapy (CET) protocol combining electronic stimulation with targeted nerve blocks, Nerve Health Solution nutritional supplements, and a turnkey Solutions Program for healthcare providers including training, marketing, and operational support.

Product overview

Neurogenx offers a portfolio of products and services centered on its FDA-cleared NervePro 2.0 electromedical device for neuropathy treatment. The core offering includes the NervePro 2.0 device that delivers high-frequency electronic wave therapy via the proprietary Combination Electrochemical Therapy (CET) protocol. This can be enhanced with an Integrated Nerve Block using targeted anesthetic injections. The company also provides the Neurogenx Nerve Health Solution, a nutritional supplement supporting nerve health through Nitric Oxide enhancement. The Neurogenx Solutions Program is a comprehensive turnkey business package offering providers marketing resources, training, software integration, and operational support to integrate neuropathy treatment into their practices.

Differentiator

Problem solved

Functional benefit

Brands

• NervePro 2.0: FDA-cleared medical device using high-frequency electronic wave technology for neuropathy treatment. The NervePro 2.0 is the primary treatment device used in Neurogenx protocols.
• Nerve Health Solution
• Neurogenx Solutions Program

Products and services

• Neurogenx NervePro 2.0 Medical Device FDA-cleared electromedical device used by healthcare providers to deliver high-frequency electronic wave therapy via transcutaneous adhesive electrode patches for treatment of neuropathy symptoms including pain, numbness, burning, tingling, cramping, and hypersensitivity. Designed for purchase by neurologists, primary care physicians, podiatrists, and chiropractors.
• Combination Electrochemical Therapy (CET) Protocol Proprietary clinical treatment protocol delivered via the NervePro 2.0 device that pairs electronic signal therapy with targeted low-dose anesthetic nerve blocks to address neuropathy at the cellular level, promote depolarization, and accelerate healing results. Administered in-office by licensed healthcare providers.
• Neurogenx Nerve Health Solution Supplement Nutritional supplement containing L-Arginine and L-Citrulline to enhance Nitric Oxide production, designed to support nerve health, improve circulation, and reduce numbness and pain in extremities. Distributed exclusively through healthcare professionals at wholesale pricing, with retail pricing for patients.
• Neurogenx Solutions Program (Provider Onboarding & Support) Turnkey business solution for healthcare providers that includes customized digital marketing, clinical and operational training, financing software, and practice integration support to help physicians add Neurogenx neuropathy treatment to their practices. Offered in two tiers: Preferred Provider (single unit) and NerveCenter (multi-unit standalone model with geographical exclusivity).

Quantifiable outcome

• 87% of patients experience complete resolution or significant reduction in neuropathy symptoms (pain, numbness, burning, tingling, cramping, hypersensitivity)
• +4 more outcomes

Named customers5 records

Segments5 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Scale indicators10 records

Recent moves6 records

Expansion highlights6 records

Emerging players

• BioElectronics Corporation: BioElectronics develops pulsed electromagnetic frequency (PEMF) and neuromodulation devices for pain and inflammation, positioned as an emerging competitor in the over-the-counter / practitioner-channel electrical therapy space.

Regional players

• Medi-Direct International: Medi-Direct distributes neuropathy-specific diagnostic and conservative-therapy solutions across the UK/Europe, indirectly comparable to Neurogenx as a neuropathy-focused clinical offering in a non-US geography.

Direct peers

• Cala Health: Cala Health markets TAPS (transcutaneous afferent patterned stimulation) therapy devices initially for essential tremor and expanding into other neurological indications, competing with Neurogenx as a wearable neurostimulation prescription product.
• SPR Therapeutics: SPR Therapeutics develops minimally invasive peripheral nerve stimulation systems (e.g., SPRINT PNS) for chronic pain and neuropathy, overlapping directly with Neurogenx's peripheral nerve therapy focus and provider channel.
• NeuroMetrix: NeuroMetrix commercializes wearable neurostimulation devices (e.g., Quell) and point-of-care nerve conduction diagnostics (DPNCheck) directly addressing chronic neuropathic pain and diabetic peripheral neuropathy — the same condition Neurogenx targets, making it the most directly comparable peer.
• ElectroCore: ElectroCore sells non-invasive vagus nerve stimulation (nVNS) devices (GammaCore) for migraine, cluster headache, and other conditions; it is comparable to Neurogenx as a non-invasive, transcutaneous electrical nerve stimulation prescription therapy company.
• Zynex Medical: Zynex Medical designs and sells prescription electrotherapy devices (TENS, NMES) and monitors used for chronic pain management, operating in the same prescription-channel electrical nerve stimulation category as Neurogenx.

Broad incumbents

• Abbott Neuromodulation: Abbott (including the former St. Jude Medical neuromodulation portfolio) offers implantable neurostimulation devices for chronic pain and movement disorders; it competes with Neurogenx for the same patient population as a much larger, well-capitalized incumbent.
• Nevro: Nevro is an established neuromodulation company (HF10 spinal cord stimulation) targeting chronic pain; while invasive, it competes with Neurogenx for the same chronic neuropathic pain patient population and the same neurology/pain provider channels.
• Enovis (DJO Global): Enovis, successor to DJO Global, is a diversified orthopedic and electromedical device manufacturer selling a broad portfolio of electrotherapy and rehabilitation products; comparable to Neurogenx as a much larger electromedical device incumbent with overlapping provider channels.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/neurogenx
• Facebookfacebook.com/neurogenxinc

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Neurogenx